Product Description
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
AI Product Description
*The following content is generated by AI and is for reference only.
Tirzepatide, developed by Eli Lilly and Company, represents a groundbreaking advancement in the treatment of metabolic disorders. Chemically known as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it is a synthetic peptide consisting of 39 amino acids with a molecular weight of approximately 4,862 g/mol. Its unique molecular structure features a fatty acid diacid moiety attached to a modified GIP analog, which facilitates albumin binding and extends its half-life, allowing for once-weekly subcutaneous administration. The CAS number for Tirzepatide is 2074358-97-1, serving as a critical identifier for regulatory and pharmaceutical tracking purposes.
Originally approved by the U.S. Food and Drug Administration (FDA) in May 2022 under the brand name Mounjaro, Tirzepatide was indicated for improving glycemic control in adults with type 2 diabetes mellitus. Subsequently, in November 2023, it received approval under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight conditions accompanied by at least one weight-related comorbidity. Clinical trials have demonstrated that Tirzepatide offers superior efficacy compared to existing GLP-1 monotherapies, often achieving significant reductions in HbA1c levels and substantial body weight loss, sometimes exceeding 20% in clinical settings.
The mechanism of action involves simultaneous activation of both GIP and GLP-1 receptors. This dual agonism enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety in the central nervous system. By targeting these two distinct pathways, Tirzepatide addresses multiple physiological factors contributing to hyperglycemia and obesity more comprehensively than single-target agents. While generally well-tolerated, common side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation. As a peptide-based biologic, it requires refrigeration prior to use and must be administered via pre-filled pens. Tirzepatide marks a paradigm shift in endocrinology, offering a potent therapeutic option for patients struggling with complex metabolic challenges where traditional therapies have fallen short.